|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | M.D. Anderson Cancer Center |
|---|---|
| Collaborator: |
Zila Biotechnology |
| Information provided by: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT00537199 |
Purpose
Primary Objectives:
Secondary Objectives:
| Condition | Intervention | Phase |
|---|---|---|
|
Head and Neck Cancer Oropharynx Cancer |
Other: Visual Examination Drug: OraTest |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Open Label, Single Group Assignment |
| Official Title: | Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401) |
| Enrollment: | 1 |
| Study Start Date: | February 2007 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
OraTest + Visual Exam
OraTest dye
|
Other: Visual Examination
Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
Drug: OraTest
Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 45 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| United States, Texas | |
| U.T.M.D. Anderson Cancer Center | |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: | Mark Chambers, DMD | U.T.M.D. Anderson Cancer Center |
More Information
| Responsible Party: | U.T. M.D. Anderson Cancer Center ( Mark S. Chambers, MD / Professor ) |
| Study ID Numbers: | 2005-1008 |
| Study First Received: | September 26, 2007 |
| Results First Received: | December 11, 2009 |
| Last Updated: | December 11, 2009 |
| ClinicalTrials.gov Identifier: | NCT00537199 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Head And Neck Oropharynx Oral Cancer OraTest |
OraTest Dye Rinse Staining Procedure Visual Examination |
|
Neoplasms Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Neoplasms by Site Head and Neck Neoplasms |
Pharyngeal Neoplasms Stomatognathic Diseases Pharyngeal Diseases Oropharyngeal Neoplasms |